Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company ...

As July draws to a close, it's time to take a look at what's in store in the health and wellness space over the upcoming weeks.August, the last month of summer, includes several ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Argenx Se, with a price target of $750.00. The company’s shares closed last Friday at $591.99. Take advantage ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...

Mirum Pharmaceuticals MIRM has delivered a stellar performance over the past three months. Shares of the company have rallied 35% compared with the industry’s rise of 6.9%. The stock has also ...

Travere Therapeutics today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the FSGS community.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equit ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported a loss of $41.2 million in its first quarter. The San Diego-based company said it had a loss of 47 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported a loss of $41.2 million in its first quarter. The San Diego-based company said it had a loss of 47 ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported a loss of $41.2 million in its first quarter. The San Diego-based company said it had a loss of 47 ...